"Through June of this year, the cholesterol-lowering drug rosuvastatin (Crestor, AstraZeneca) was the most prescribed branded drug in the United States, and the arthritis drug adalimumab (Humira, Abbott Laboratories) was the best-sel"...
Physostigmine Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Physostigmine Salicylate Injection is an antidote used to reverse the effect of drugs that cause anticholinergic syndrome. Common side effects of physostigmine salicylate include nausea, vomiting, salivation, stomach cramps, diarrhea, and excessive sweating.
The recommended dosage of physostigmine salicylate is 0.5 to 1.0 mg. Other drugs may interact with physostigmine salicylate. Tell your doctor all medications you take. Before taking physostigmine salicylate tell your doctor if you have sulfite sensitivity. If you are pregnant or breastfeeding only take physostigmine salicylate if the potential benefits outweigh the potential risks.
Our Physostigmine Salicylate Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Physostigmine FDA Prescribing Information: Side Effects
Nausea, vomiting and salivation; can be offset by reducing dosage. Bradycardia and convulsions, if intravenous administration is too rapid. See DOSAGE AND ADMINISTRATION.
Read the entire FDA prescribing information for Physostigmine (Physostigmine Salicylate (injection))
Additional Physostigmine Salicylate Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.